914656-05-6Relevant articles and documents
Quinoline derivatives as neurokinin receptor antagonists
-
Page/Page column 54, (2009/04/24)
The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R1, R2, R3, R4, R5, X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.
N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II
Elliott, Jason M.,Carling, Robert W.,Chicchi, Gary G.,Crawforth, James,Hutson, Peter H.,Jones, A. Brian,Kelly, Sarah,Marwood, Rose,Meneses-Lorente, Georgina,Mezzogori, Elena,Murray, Fraser,Rigby, Michael,Royo, Inmaculada,Russell, Michael G.N.,Shaw, Duncan,Sohal, Bindi,Tsao, Kwei Lan,Williams, Brian
, p. 5752 - 5756 (2007/10/03)
Introduction of selected amine containing side chains into the 3-position of N′,2-diphenylquinoline-4-carbohydrazide based NK3 antagonists abolishes unwanted hPXR activation. Introduction of a fluorine at the 8-position is necessary to minimize unwanted hIKr affinity and a piperazine N-tert-butyl group is necessary for metabolic stability. The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ90 7 mg/kg po; plasma Occ90 0.4 μM) and has good selectivity and excellent PK properties.